loading

Finanzdaten der Janux Therapeutics Inc-Aktie (JANX)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
-
- - 0.439 8.897
Research and Development
38.35%
34.66
25.05 - - -
Operating Income/Loss
29.29%
-45.12
-34.90 -29.02 -35.84 -13.82
Nonoperating Income/Loss
1.13%
11.26
11.39 8.806 7.783 7.863
Income/Loss From Continuing Operations Before Tax
44.03%
-33.86
-23.51 -20.22 -28.06 -5.959
Income/Loss From Continuing Operations After Tax
44.03%
-33.86
-23.51 -20.22 -28.06 -5.959
Net Income/Loss
44.03%
-33.86
-23.51 -20.22 -28.06 -5.959
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
0.18%
61.90
61.79 1.0345 54.63 54.45
Diluted Average Shares
0.18%
61.90
61.79 1.0345 54.63 54.45
Basic Earnings Per Share
44.74%
-0.55
-0.38 -0.35 -0.51 -0.11
Diluted Earnings Per Share
44.74%
-0.55
-0.38 -0.35 -0.51 -0.11
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$21.43
price down icon 2.44%
$87.67
price up icon 0.29%
$32.80
price up icon 0.27%
$104.27
price down icon 0.88%
$162.90
price down icon 0.07%
biotechnology ONC
$315.23
price down icon 1.40%
Kapitalisierung:     |  Volumen (24h):